JNJ Stock Stuck in Narrow Range Ahead of Earnings Report
Johnson & Johnson's (JNJ) stock has been trading in a narrow range after a 3% decline last week, which landed the company in oversold territory according to momentum signals. The recent drop has brought conflicting technical cues, indicating both downside exhaustion and unresolved pressure as the market heads into an earnings-sensitive week.
The pharmaceutical giant's shares are expected to trade between $258.74 and $274.82 over the next five trading days, with a 53% probability of an increase and a 47% chance of a decrease. Analysts expect Johnson & Johnson to report earnings of $2.48 per share and revenue of $25.31 billion in its upcoming third-quarter earnings report.
The company's efforts to strengthen its pharmaceutical pipeline through recent clinical successes, including positive data for Tremfya and Carvykti, as well as a strong showing from Caplyta following the $14.6 billion Intra-Cellular Therapies acquisition, are expected to support sentiment in the week ahead.